Amino Acid, Peptide, or Protein
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment
FDA Approves New Oral Alzheimer’s Therapy, Expands Label for Grifols SCIg Therapy
FDA, Alzheimer’s disease, Grifols, XEMBIFY, immunoglobulin, subcutaneous, immunodeficiency, plasma-derived therapeutics
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy
FDA Advisers Call for Revamp of Perioperative Lung Cancer Trials Due to Frustration with AstraZeneca’s Imfinzi Design
FDA, Imfinzi, AstraZeneca, perioperative lung cancer trials, revamp, design issues
Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata
Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology
Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent
Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis
EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead
Wegovy, EU panel, FDA, cardiac events, weight loss, Novo Nordisk
Pfizer Expands API Manufacturing Site in Singapore with $740M+ Investment
Pfizer, API manufacturing, Singapore, facility extension, investment
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment